Drug Profile


Alternative Names: ESK1 monoclonal antibody - Eureka Therapeutics/Memorial Sloan Kettering Cancer Center; ESKM; Fc-enhanced TCR-like antibody - Novartis; Intracellular WT 1 targeting anticancer therapeutics - Novartis

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Eureka Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Monoclonal antibodies
  • Mechanism of Action Intracellular signalling peptide and protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Mesothelioma
  • No development reported Leukaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Leukaemia in USA (Parenteral)
  • 13 Mar 2013 Preclinical trials in Leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top